1. Introduction {#sec1}
===============

Bariatric surgery represents a highly successful treatment strategy for obesity and secondary diseases such as type 2 diabetes mellitus (T2DM), at least in morbidly obese patients \[[@B1]\]. Though similar effects may be obtained with lifestyle intervention \[[@B2]\], many morbidly obese patients do not succeed in making sufficient permanent lifestyle changes \[[@B3]\]. The success rate of surgery varies depending on the surgical procedure and individual factors including lifestyle/nutrition, age, gender, and genetics/epigenetics \[[@B4], [@B5]\]. Besides being an effective treatment for obesity that decreases mortality and morbidity, bariatric surgery confers some health risk including renal stone formation and oxalate nephropathy (calcium oxalate crystals in the kidney) \[[@B6]\]. Due to changes to the gastrointestinal tract with malabsorptive surgery, absorption of vitamins and minerals is affected and bariatric surgery patients are advised to take micronutrient supplements \[[@B7]\].

It is of utmost importance to fully understand the metabolic changes induced by bariatric surgery, as it may lead to novel treatment strategies for obesity and related health problems. Because morbidly obese patients undergoing bariatric surgery effectively and consistently lose excess body weight and reduce obesity-related comorbidity, they represent a very useful patient group for studying mechanisms that regulate metabolic health. The most common surgical procedures are today performed laparoscopically and include adjustable gastric band (LAGB), sleeve gastrectomy (LSG), Roux-en-Y gastric bypass (RYGB), and biliopancreatic diversion (BPD). BPD often includes duodenal switch (BPD/DS) and sleeve gastrectomy. RYGB and BPD show the best long-term results in terms of fat loss \[[@B8], [@B9]\] and diabetes resolution \[[@B1]\]. Whereas LAGB and LSG exert their effects through reduced ventricular volume and food intake, RYGB and BPD (with sleeve gastrectomy) combine this effect with malabsorption of nutrients by means of bypassing a substantial part of the small intestine. In addition, the intestinal reconfiguration results in a rapid improvement of diabetes within days in most patients, which cannot be entirely ascribed to energy restriction or fat loss \[[@B10]\]. This intriguing observation has led to the hypothesis that regulatory factors in the small intestine, including peptide hormones and nerve signals, are critical in modulating glucose homeostasis. Thus, the metabolic effects of bariatric surgery are both dependent and independent of fat loss.

In the present paper, our overall aim was to describe central mechanisms that may mediate the beneficial effects of bariatric surgery on metabolic health. Our specific objective was first to summarize the most important findings regarding fat loss-independent effects of bariatric surgery. Because of the scarcity of data on the acute effects of surgery on various metabolic parameters, we also discuss longer-term metabolic effects that may result from a combination of fat loss and intestinal surgery, including effects on mitochondria. Finally, our objective was to provide new perspectives for future research regarding the metabolic effects of bariatric surgery.

2. Acute Metabolic Effects of Bariatric Surgery {#sec2}
===============================================

In the weeks following bariatric surgery, patients are limited to consumption of liquids and their nutrient intake becomes drastically reduced. Thus, when evaluating the metabolic effects of bariatric surgery, one must consider the isolated impact of reduced energy intake versus weight loss. In healthy lean subjects, energy restriction may induce a "starvation diabetes" marked by hepatic and peripheral insulin resistance \[[@B11]\]. In obese individuals, on the other hand, energy restriction may improve glycemic control and insulin sensitivity independently of weight loss during the first days \[[@B12]\]. The metabolic effects of weight loss may begin to be substantial after 7--10 days of energy restriction \[[@B13]\]. In diabetic obese individuals, four days of energy restriction improved hepatic insulin sensitivity leading to suppressed hepatic glucose output and reduced fasting glucose levels \[[@B14]\].

However, energy restriction cannot fully account for the acute improvement in glycemic control after intestinal bypass. Studies comparing intestinal bypass (RYGB) to energy-restrictive procedures, both of which require patients to consume only liquids in the first weeks postsurgery, show a specific acute effect on glucose metabolism after RYGB. In contrast to RYGB \[[@B5], [@B15]\], the LAGB procedure showed no amelioration of diabetes until a considerable degree of weight loss had occurred in a randomized controlled trial of obese diabetic patients \[[@B16]\]. Kashyap et al. showed that only RYGB and not LSG improved postprandial insulin secretion and sensitivity despite similar reductions in weight and fasting insulin levels (subjects were compared 1--3 weeks before versus 1 week after surgery) \[[@B17]\]. Similarly, a randomized controlled trial of diabetic patients by Peterli et al. showed that RYGB but not LSG increased meal-induced insulin responses 1 week postsurgery, while effects of the different surgical procedures were similar at 3 months, when similar weight loss was achieved \[[@B18]\]. These observations clearly point towards mechanisms of acute glucose control that are unique to intestinal bypass and that are independent of energy restriction and weight loss.

The acute effects of bariatric surgery on glycemic control and metabolic health likely involve a combination of several factors, including insulin secretion, peripheral insulin sensitivity, and hepatic insulin sensitivity. Distinct effects have been observed with the BPD and RYGB procedures. The effects of BPD are more due to intestinal reconfiguration and malabsorption, while RYGB involves a greater restriction of gastric volume (to 30 ml versus 300--400 ml with BPD). BPD rapidly improved insulin sensitivity along with a reduction in insulin secretion and normalization of blood glucose levels 1 week \[[@B19]\] as well as 1 month postsurgery, measured by euglycemic-hyperinsulinemic clamp \[[@B20]\]. On the other hand, RYGB did not improve peripheral insulin sensitivity 2 weeks or 1 month postsurgery, also measured by euglycemic-hyperinsulinemic clamp \[[@B21], [@B22]\]. Rather, RYGB may acutely reduce hyperglycemia by increasing food-induced insulin secretion via increased release of incretins \[[@B18], [@B23]\], in some cases resulting in episodes of hypoglycaemia \[[@B24], [@B25]\]. It should be noted that another study of RYGB patients before versus 6 days after surgery found significant improvement in peripheral insulin sensitivity measured by intravenous glucose tolerance tests and homeostatic model assessment (HOMA) \[[@B15]\]. However, euglycemic-hyperinsulinemic clamp is a superior technique for measuring insulin resistance. It is possible that improvements in hepatic rather than peripheral insulin sensitivity may represent a key mechanism of glucose control after RYGB. A study in mice suggested that restoration of glucose control after RYGB may be due to reduced endogenous glucose output via improved hepatic insulin sensitivity, and also altered intestinal gluconeogenesis \[[@B26]\].

The proposed hypotheses attempting to explain the surgery-specific effects on glucose metabolism remain speculative. Various mechanisms are likely to contribute \[[@B10]\]. The lower intestinal (hindgut) hypothesis proposes that exclusion of the proximal intestine leads to a more rapid delivery of nutrients to the lower intestine, resulting in increased release of gut hormones that regulate glucose metabolism (e.g., glucagon-like peptide-1 (GLP-1), peptide Y (PYY), and oxyntomodulin secreted by L-cells in the distal small intestine and parts of the colon) \[[@B27], [@B28]\]. It is possible that central effects of GLP-1 may contribute to reducing hepatic insulin resistance and glucose production \[[@B29]\]. Importantly, a stimulatory effect on the circulating levels of incretins such as GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), which augment insulin secretion, was not observed with energy restriction in diabetic patients \[[@B23]\]. It is interesting to note that secretion of GIP, which is produced in K-cells in the proximal intestine, was found to be increased after RYBG \[[@B27]\] but decreased after BPD \[[@B19], [@B20]\]. GIP has been shown to promote energy storage in adipose tissue, and inactivation of GIP in mice was shown to improve insulin resistance \[[@B30]\]. Moreover, the upper intestinal (foregut) hypothesis postulates that the proximal intestine that is bypassed with RYGB and BPD releases one or more factors with adverse effects on glucose metabolism. In polygenic diabetic rats (Goto-Kakizaki), Rubino et al. found that duodenal-jejunal bypass enhanced glucose metabolism independently of food intake and body weight \[[@B31]\]. The mechanism may involve reduced nutrient contact with the excluded duodenum \[[@B32]\]. In diabetic humans with a 60 cm flexible plastic sleeve inserted to inhibit nutrient contact with duodenal mucosa (endoluminal duodenal sleeve), glycemic control both after and between meals improved considerably already after 1 week without significant weight loss \[[@B33]\].

Neuronal signalling has been implicated as a critical factor in the postsurgery control of glucose metabolism. The vagus nerve is a critical regulator of the digestive process as well as of appetite regulation in the gut-brain-gut axis, and vagotomy (resection of the vagus nerve) has been used to treat obesity \[[@B34]\]. More recently, blockage of vagus activity by an implanted medical device has shown promising effects on weight loss in humans \[[@B35]\]. Randomized controlled trials are needed to confirm this effect, and possible acute effects on glucose metabolism would be of particular interest. An acute effect of vagotomy to reduce insulin secretion was demonstrated several decades ago in rats \[[@B36]\]. Hepatic glucose production is centrally regulated via the hepatic branch of the vagus nerve \[[@B37]\]. Thus, vagus nerve function may at least partially mediate the acute effects of intestinal bypass surgery on glucose metabolism.

3. Long-Term Effects on Insulin Sensitivity, Glucose Metabolism, and Metabolic Tissues {#sec3}
======================================================================================

While it is difficult to isolate the fat loss-dependent and independent effects of bariatric surgery, long-term studies of bariatric patients indicate that a greater loss of excess body weight associates with an improved effect on diabetes \[[@B1]\]. When performed in morbidly obese patients, the RYGB and BPD/DS procedures often reduce body weight to about half the original weight within the two first years, followed by a stable weight for at least 10 years \[[@B8], [@B9]\]. Although bariatric patients usually remain obese after surgery with a body-mass index (BMI) above 30, their metabolic profile is in many respects similar to that of healthy, lean individuals. A prospective study of whole body and muscle insulin sensitivity before and one year after bariatric surgery found that weight-stable RYGB patients were more comparable to lean than weight-matched controls \[[@B38]\]. However, this beneficial effect of fat loss is not specific to bariatric surgery, since shorter-term nutritional intervention and exercise have also been shown to induce weight loss-independent improvements in glucose homeostasis \[[@B39], [@B40]\]. Nonetheless, bariatric surgery allows for relatively controlled long-term prospective studies of both moderate and profound fat loss and has provided important insight into the altered functions of metabolic tissues in (morbid) obesity.

3.1. Bariatric Surgery and the Functions of Adipose Tissue and Skeletal Muscle {#sec3.1}
------------------------------------------------------------------------------

Adipose tissue performs functions that are critical to metabolic health, providing a storage buffer for surplus energy and secreting peptide hormones, cytokines, lipids and other molecules, thereby coordinating metabolic regulation with other organs \[[@B41]\]. Obesity is characterized by increased fat mass and altered adipose tissue function, involving cellular stress responses, changes in extracellular matrix, infiltration of immune cells such as macrophages, chronic inflammation, and potential aberration of adipogenesis, angiogenesis, and tissue remodelling. These changes are related to increased ectopic lipid accumulation and secretion of adipokines with potential adverse systemic effects \[[@B42], [@B43]\].

Bariatric surgery may improve adipose tissue function via various mechanisms, including an acute reduction in energy intake, changes in the endocrine and immune-related functions of the gut, and profound reductions in adipose tissue mass \[[@B44]\]. There is a paucity of information on the acute effects of bariatric surgery on adipose tissue function in humans. In cultured human subcutaneous adipocytes, GIP together with insulin was found to activate lipoprotein lipase \[[@B45]\], suggesting that altered GIP levels after bariatric surgery may affect lipid uptake in adipose tissue \[[@B46]\].

Several long-term studies of bariatric patients have revealed important insights into the alterations of adipose tissue function in obesity. Endoplasmic reticulum stress is increased in obesity, markers of which were strongly reduced in both subcutaneous adipose tissue and liver tissue 1 year after RYGB \[[@B47]\]. Moreover, a reduction in macrophage infiltration and the expression of chemoattractant and pro-inflammatory genes was observed in a global gene expression study of subcutaneous adipose tissue before versus 3 months after RYGB \[[@B48]\]. Our recent microarray study of subcutaneous adipose tissue before versus 1 year after BPD/DS corroborates these findings, showing a substantial reduction in genes related to immunity and defense functions \[[@B49]\]. These studies have also demonstrated that bariatric surgery, most likely due to the profound fat loss, strongly alters the expression of genes involved in extracellular matrix functions \[[@B49], [@B50]\]. While similar observations have been made in dietary intervention studies \[[@B51], [@B52]\], the differential gene expression after bariatric surgery may be specific to the extreme degree of fat loss and possibly also some effects of the gastrointestinal changes after surgery.

Muscle insulin resistance may be a critical factor in the pathogenesis of diabetes and metabolic complications including fatty liver \[[@B53]\]. Bariatric surgery was found to decrease intramyocellular lipids measured by Oil-red-O staining 3 and 9 months after RYGB or LAGB \[[@B54]\]. The study also found reduced gene expression of *SCD1* and *PDK4* in skeletal muscle after 3 months, whereas *PPAR*α**, *MCAD*, *CPT1*, and *UCP3* were down-regulated only at the 9-month time point. Greco et al. showed a significant reduction in intramyocellular lipids 6 months after BDP \[[@B55]\]. A magnetic resonance spectroscopy study also found significant reductions in intramyocellular lipids already 1 month after BPD \[[@B56]\], while this early effect was not reported in a study of seven RYGB patients \[[@B57]\]. Further studies should be performed to verify whether there is a surgery-specific effect on intramyocellular lipids. It is tempting to speculate whether a reduced circulating level of GIP specifically after BPD may play a role, since suppression of GIP may reduce lipid storage in skeletal muscle and liver as in adipose tissue \[[@B46]\].

3.2. Bariatric Surgery and Liver Function {#sec3.2}
-----------------------------------------

The liver is a critical organ for maintaining metabolic homeostasis in the body. Lipid homeostasis is typically disrupted in obese individuals, reflected by chronically elevated plasma lipid levels. Together with adipose tissue, the liver is the main lipidemic organ during systemic hyperlipidimia, and the development of insulin resistance and diabetes \[[@B58]\]. The liver takes up free fatty acids (FFAs) released from adipose tissue, as well as circulating triglycerides (TGs). The FFAs are either degraded by *β*-oxidation or repackaged to TGs in very low-density lipoprotein particles and released into the bloodstream.

Steatosis (fatty liver) occurs when there is an imbalance between lipogenesis and fatty acid oxidation. When the rate of hepatic fatty acid uptake from plasma and *de novo* fatty acid synthesis predominates over the rate of fatty acid oxidation and triglyceride export, triglycerides will be deposited in the liver. The resulting liver injury is often associated with obesity, and 95% of individuals with class III obesity (BMI ≥ 40 kg/m^2^) have alterations in routine liver biopsies due to steatosis, steatohepatitis, or fibrosis \[[@B59]\]. These liver abnormalities are known as nonalcoholic fatty liver disease (NAFLD) which increases the risk of developing T2DM, dyslipidemia, and hypertension \[[@B60]\]. It is unknown whether alterations in hepatic glucose, FA, and lipoprotein metabolism and inflammation are causes of NAFLD, or whether these abnormalities are increased in the presence of NAFLD. Increased hepatic *β*-oxidation will generate reactive oxygen species and promote the development from steatosis to the inflammatory stage nonalcoholic steatohepatitis (NASH). Reduced lipid storage efficiency in adipose tissue and increased rates of adipose tissue lipolysis in obesity promote ectopic lipid accumulation, challenging the liver with high amounts of FFAs \[[@B43]\].

The amelioration of NAFLD and liver function by bariatric surgery may be an important contributor to the systemic improvement of energy homeostasis. Most studies have shown improved liver histology and liver function as well as insulin sensitivity in obese subjects with NAFLD and NASH after bariatric surgery \[[@B61]\]. The weight loss and reduced energy overload improve liver parameters, and the less severe steatosis is fully reversible. In accordance with this, LAGB changed the hepatic adipokine levels of NAFLD patients in an anti-inflammatory direction, increased the adiponectin protein level, and decreased the leptin receptor mRNA level 6 months after surgery \[[@B62]\]. Another study found that a gene with a central role in lipid peroxidation, *CYP2E1*, was significantly reduced in liver after weight loss following bariatric surgery \[[@B63]\]. Hepatic lipid peroxidation, as measured by the malondialdehyde (MDA) level, was reduced and liver steatosis decreased from 17% prior to surgery to 2% several months after. These studies show that bariatric surgery can improve the more progressed NASH disease. The amelioration of NAFLD and liver function by bariatric surgery may be an important contributor to the systemic improvement of energy homeostasis. However, the lack of randomized clinical trials so far makes it difficult to conclude on the use of bariatric surgery for treatment of NASH \[[@B64]\].

Intriguingly, no reduction in intrahepatocellular lipid levels was observed 1 month after RYGB while insulin sensitivity markedly improved \[[@B57]\]. This was surprising given the strong link between hepatic lipid levels and insulin resistance. On the other hand, hepatic lipid content was markedly reduced by 6 and 12 months. Of note, neither visceral adipose tissue mass nor intramyocellular lipid levels correlated with the improvements in insulin sensitivity. These observations should be validated in short-term randomized studies with increased power and in subjects undergoing different forms of bariatric surgery. This may provide important new insight into the mechanisms whereby bariatric surgery affects the systemic metabolic homeostasis via the individual metabolic tissues. Development of insulin resistance in the liver may also partly result from the altered secretion of metabolic and inflammatory adipokines from adipose tissue \[[@B58], [@B65]\]. The general metabolic effects of bariatric surgery are summarized in [Figure 1](#fig1){ref-type="fig"}.

4. Mitochondria in Obesity and Diabetes Mellitus {#sec4}
================================================

4.1. Mitochondria before Bariatric Surgery {#sec4.1}
------------------------------------------

Mitochondrial metabolism is essential in maintaining normal physiological function in human cells, for example, by providing energy in the form of ATP and performing fatty acid (FA) oxidation. These metabolic functions are reduced in insulin-responsive tissues (muscle and adipose tissue) in obesity and T2DM. No consensus has been reached so far whether insulin resistance is a result of reduced mitochondrial density and whether it is the cause or consequence of mitochondrial dysfunction \[[@B66]--[@B76]\]. In general, insulin regulates protein synthesis, glycolysis, and glucose storage in muscle and liver, lipid synthesis, and storage in liver and adipose tissue, and inhibits gluconeogenesis and ketogenesis in liver \[[@B77]\]. In particular, insulin signalling was shown to influence mitochondrial DNA and protein synthesis and affect mitochondrial respiration and ATP production \[[@B78]\]. Factors that may cause mitochondrial dysfunction include genetic defects, age, physical inactivity, and nutritional overload. These factors may exert changes in mitochondrial size and content, activity and coupling of mitochondrial respiration, copy numbers of the mitochondrial genome, reactive oxygen species (ROS) production, FA oxidation, and more.

Altered gene expression and protein levels may reflect the status of mitochondrial function in obesity and related diseases. Reduced expression of specific genes in myocytes was proposed to result in mitochondrial dysfunction in patients with T2DM. For example, the expression of several genes encoding enzymes involved in the electron transport chain was reduced in muscle of family history-positive nondiabetic subjects and subjects with T2DM \[[@B79], [@B80]\]. However, this reduced mRNA expression was not reflected in a reduced respiratory rate per mitochondrion in insulin-resistant muscle \[[@B66]\]. The expression of several genes of the FA oxidation pathway was also decreased in skeletal muscle in T2DM \[[@B80]\]. Moreover, genes related to mitochondrial biogenesis, such as peroxisome proliferator-activated receptor *γ* coactivator-1 (*PGC-1*α** and *PGC-1β*), were similarly down-regulated in diabetes \[[@B79], [@B80]\]. Another study attributed the decreased skeletal muscle FA oxidation in obesity to reduced mitochondrial content (and not to intrinsic mitochondrial defects), but showed no reduction in the protein levels of PGC-1**α**, PGC-1*β*, peroxisome proliferator-activated receptor **α** (PPAR**α**), or the mitochondrial transcription factor A (TFAM). Instead, the protein level of PPAR*γ* was increased, possibly due to decreased FA oxidation \[[@B81]\]. Furthermore, it has been proposed that mitochondrial fusion and metabolism in obese and non-obese T2DM patients is impaired due to reduced expression of mitofusin 2 (MFN2) in skeletal muscle \[[@B82]--[@B84]\]. MFN2 is an outer mitochondrial- and endoplasmic reticulum membrane protein with fusion activity important for mitochondrial dynamics and morphology \[[@B83]--[@B85]\]. MFN2 transcriptional activation is regulated by both PGC-1**α** and *β* and the estrogen-related receptor **α** (ERR**α**). More studies are needed to delineate the molecular mechanisms responsible for altered mitochondrial function in obesity.

It is of potential interest to compare different adipose tissue depots regarding mitochondrial function. Increased visceral (intra-abdominal) adipose tissue mass is particularly associated with risk of metabolic disease relative to subcutaneous fat. Diabetic humans show decreased expression of respiratory rate genes in visceral adipose tissue compared to healthy humans \[[@B86]\]. It has also been shown that visceral adipose tissue contains twice as many, but smaller, mitochondria per milligram of tissue than the subcutaneous depot \[[@B86]\]. This resulted in visceral fat eliciting lower mitochondrial respiration than subcutaneous fat, when expressed per cell. However, per milligram tissue visceral fat was metabolically more active than subcutaneous fat.

4.2. Mitochondrial Regulatory Pathways and Biogenesis after Bariatric Surgery {#sec4.2}
-----------------------------------------------------------------------------

Mitochondrial function is destabilized in obesity and T2DM, but few studies have specifically investigated the effect of bariatric surgery on mitochondrial metabolism in myocytes and adipocytes. Bariatric surgery has been shown to induce severalfold changes in the expression of genes encoding proteins involved in mitochondrial function and biogenesis in muscle and adipose tissue. In a global gene expression study of subcutaneous adipose tissue before versus 1 year after BPD/DS \[[@B49]\], we observed an altered expression of certain genes involved in the mitochondrial electron transport chain. These alterations included an up-regulation after surgery of *ATP5G2*, which encodes a subunit of the mitochondrial ATP synthase, and of *COX5B*, the nuclear-encoded Vb subunit of the cytochrome c oxidase (COX) complex. The multi-subunit COX complex transfers electrons from cytochrome c (CYCS) to molecular oxygen to form water. The expression of *CYCS*, on the other hand, which is also an intermediate in apoptosis, was down-regulated in adipose tissue after bariatric surgery. In addition, three genes of the solute carrier family (*SLC25A25*, *SLC25A37*, *SLC25A44*), involved in shuttling phosphate, iron, and adenine nucleotides across the inner mitochondrial membrane, were significantly down-regulated postsurgery. Another study investigated alterations in skeletal muscle mitochondrial function two years after BPD surgery, comparing morbidly obese patients to patients with normal glucose tolerance (NGT) and T2DM \[[@B87]\]. It was demonstrated that BPD surgery increased insulin sensitivity in both NGT and T2DM patients, an effect that did not correlate with induced mitochondrial gene expression in the diabetic patients ([Figure 2](#fig2){ref-type="fig"}). NGT patients showed an increased expression of genes regulating mitochondrial biogenesis in skeletal muscle, including *PGC-1*α**, *PGC-1β*, *PPAR*δ**, and *SIRT1* (a gene that regulates PGC-1**α**expression in liver and muscle) \[[@B87]\]. The expression of other mitochondrial genes such as *MFN2* and the constitutive genes porin (*VDAC1*) and citrate synthase (*CS*) were also significantly increased in the NGT patients. In the diabetic patients, no change was observed with the exception of *MFN2* which was down-regulated. Moreover, a differential oxidative profile in line with the mitochondrial gene expression could be observed in the two groups. Glucose oxidation during fasting was higher in the NGT group and lipid oxidation was higher in the diabetic group after BPD surgery. These results suggest a differential regulation of mitochondrial function in response to BPD in patients with NGT and T2DM, respectively.

5. Future Perspectives {#sec5}
======================

Many aspects of the metabolic effects of bariatric surgery remain inadequately addressed or unanswered. There is convincing evidence that bariatric surgery exerts acute effects on metabolism that are independent of energy restriction and fat loss. The role of incretins on the metabolic functions of the liver, adipose tissue, and skeletal muscle should be further investigated. Molecular biology tools including global gene expression analysis and proteomics should be applied on tissue biopsies and isolated cell fractions collected before and shortly after bariatric surgery. Since certain biopsies are difficult to obtain from humans (e.g., postoperative visceral fat), the rat may be a useful model for studying the acute as well as long-term metabolic effects of bariatric surgery in all tissues \[[@B88]--[@B90]\]. In humans, short-term randomized controlled trials with increased power and direct comparison of different surgical procedures should be performed, and these would be strengthened by simultaneous measurement of tissue-specific metabolic parameters. More detailed analysis of parameters such as mitochondrial function may reveal novel mechanisms that may be targeted for more successful treatment of obesity and related diseases. The acute and long-term effects of specific bariatric surgery procedures on tissue and mitochondrial functions should be further investigated.
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![Scheme of the metabolic changes in response to adjustable gastric band (AGB) and laparoscopic sleeve gastrectomy (LSG), whose metabolic effects are mainly dependent on weight loss, and Roux-en-Y gastric bypass (RYGB) and biliopancreatic diversion (BPD), whose metabolic effects are also independent of weight loss.](JOBES2011-435245.001){#fig1}

![Summary of altered mitochondrial and mitochondrial biogenesis (boxed) gene expression in skeletal muscle of morbidly obese patients with normal glucose tolerance or type 2 diabetes mellitus (T2DM) \[[@B87]\] and in subcutaneous adipose tissue (SAT) one year after BPD/DS surgery \[[@B49]\]. Arrows indicate the direction of the altered gene expression after bariatric surgery.](JOBES2011-435245.002){#fig2}
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